Combined use of ECT with aripiprazole

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Schizophrenia is a chronic mental disorder often requiring multifaceted treatment approaches.
• Refractory schizophrenia presents significant challenges, necessitating exploration of novel therapeutic strategies.
• Aripiprazole, a partial dopamine agonist, is used in schizophrenia management, but its augmentation with ECT is less studied.

Observation:

• A 30-year-old male patient with chronic, treatment-resistant paranoid schizophrenia exhibited persistent agitation, suspiciousness, and obsessive fears despite high-dose antipsychotic therapy.
• Electroconvulsive treatment (ECT) was initiated while the patient continued his antipsychotic regimen.
• Aripiprazole was introduced after six ECT sessions.

Findings:

• The combined treatment of ECT and aripiprazole resulted in significant clinical improvement in the patient's schizophrenic symptoms.
• Neither the convulsive threshold nor the seizure duration were substantially altered by the addition of aripiprazole.
• The combined therapeutic approach was well-tolerated by the patient, with no significant adverse events reported.

Implications:

• This case suggests that combining electroconvulsive treatment with aripiprazole may be a viable and effective strategy for managing chronic and refractory paranoid schizophrenia.
• The findings support the potential for synergistic effects between ECT and partial dopamine agonists in treatment-resistant cases.
• Further research is warranted to validate these observations in larger cohorts and to elucidate the underlying mechanisms of this combined therapeutic approach.